Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress
Provided By GlobeNewswire
Last update: Oct 22, 2024
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today presented data on its cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA (iqDNA) platforms at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress.
Read more at globenewswire.com0.44
+0.05 (+13.87%)
Find more stocks in the Stock Screener
GBIO Latest News and Analysis
17 days ago - ChartmillGet insights into the top gainers and losers of Friday's after-hours session.The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
